Immunotherapy
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Unlock global immunotherapy market insights. NovaPharmaNews delivers critical intelligence for pharma BD, investors & analysts. Stay ahead.
Showing 1–7 of 7 articles
Quick answer
NovaPharmaNews Immunotherapy hub for EMA covers 7 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
OS Therapies' OST-HER2 Nears FDA Accelerated Approval for Osteosarcoma Amidst ASCO Data Presentation
FDA Approves AstraZeneca's Imfinzi-BCG Combination for High-Risk NMIBC
Oncolytics Biotech Reports Durable Responses with Pelareorep in RAS-Mutant Colorectal Cancer Trial
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins as Strategic Adviser for DCVax Cancer Vaccine Development
Adagene's Muzastotug Shows 66.7% Response Rate in Triple Combination Therapy for Hepatocellular Carcinoma at AACR 2026
GlycoNex GNX1021 Gets PMDA Approval for First-in-Human Phase 1 Trial in Gastrointestinal Cancers
CHMP Positive Opinion CAR-T Therapy: What You Need to Know
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.